Guggenheim Has Lowered Expectations for Entrada Therapeutics (NASDAQ:TRDA) Stock Price

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) had its target price dropped by research analysts at Guggenheim from $17.00 to $13.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s price target would indicate a potential upside of 162.10% from the stock’s current price.

TRDA has been the subject of a number of other research reports. HC Wainwright reiterated a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Weiss Ratings upgraded shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Roth Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 9th. Finally, UBS Group reiterated a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Entrada Therapeutics has a consensus rating of “Hold” and an average target price of $16.75.

Check Out Our Latest Analysis on Entrada Therapeutics

Entrada Therapeutics Price Performance

TRDA stock opened at $4.96 on Wednesday. The business has a 50 day simple moving average of $5.50 and a 200-day simple moving average of $8.36. Entrada Therapeutics has a twelve month low of $4.11 and a twelve month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.07. The business had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $2.30 million. Entrada Therapeutics had a negative net margin of 4,057.98% and a negative return on equity of 64.00%. On average, equities analysts anticipate that Entrada Therapeutics will post -4.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Entrada Therapeutics

In other news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the transaction, the insider directly owned 4,318,348 shares in the company, valued at $30,487,536.88. The trade was a 0.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $7.13, for a total transaction of $205,607.81. Following the transaction, the insider directly owned 3,885,115 shares of the company’s stock, valued at $27,700,869.95. This represents a 0.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 495,947 shares of company stock valued at $3,600,470 in the last 90 days. Company insiders own 9.49% of the company’s stock.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Entrada Therapeutics during the 2nd quarter worth approximately $19,013,000. Nantahala Capital Management LLC purchased a new position in shares of Entrada Therapeutics during the 2nd quarter worth approximately $2,212,232. 5AM Venture Management LLC purchased a new position in shares of Entrada Therapeutics during the 2nd quarter worth approximately $29,854,949. GSA Capital Partners LLP acquired a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $648,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $582,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

Read More

Analyst Recommendations for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.